105 related articles for article (PubMed ID: 19860626)
1. Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors.
Richendollar BG; Tsao RE; Elson P; Jin T; Steinle R; Pohlman B; Hsi ED
Leuk Lymphoma; 2009 Dec; 50(12):2005-12. PubMed ID: 19860626
[TBL] [Abstract][Full Text] [Related]
2. Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders.
Stubbins RJ; Lam R; Zhu J; Ghosh S; Mabilangan C; Kuruvilla J; Goswami RS; Lai R; Preiksaitis JK; Jain MD; Peters AC
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):744-752. PubMed ID: 35717340
[TBL] [Abstract][Full Text] [Related]
3. Role of Epstein-Barr virus status and immunophenotypic studies in the evaluation of exfoliative cytology specimens from patients with post-transplant lymphoproliferative disorders.
Gibson SE; Picarsic J; Swerdlow SH; Pantanowitz L
Cancer Cytopathol; 2016 Jun; 124(6):425-35. PubMed ID: 26992116
[TBL] [Abstract][Full Text] [Related]
4. Increased CD200 expression in post-transplant lymphoproliferative disorders correlates with an increased frequency of FoxP3(+) regulatory T cells.
Vaughan JW; Shi M; Horna P; Olteanu H
Ann Diagn Pathol; 2020 Oct; 48():151585. PubMed ID: 32829067
[TBL] [Abstract][Full Text] [Related]
5. High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.
Saito H; Miyoshi H; Shibayama H; Toda J; Kusakabe S; Ichii M; Fujita J; Fukushima K; Maeda T; Mizuki M; Oritani K; Seto M; Yokota T; Kanakura Y; Hosen N; Ohshima K
Int J Hematol; 2021 Jul; 114(1):53-64. PubMed ID: 33765256
[TBL] [Abstract][Full Text] [Related]
6. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
8. A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation.
Fararjeh FA; Mahmood S; Tachtatzis P; Yallop D; Devereux S; Patten P; Agrawal K; Suddle A; O'Grady J; Heaton N; Marcus R; Kassam S
Eur J Haematol; 2018 Jan; 100(1):98-103. PubMed ID: 29094407
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
10. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
[TBL] [Abstract][Full Text] [Related]
11. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
Ghobrial IM; Habermann TM; Maurer MJ; Geyer SM; Ristow KM; Larson TS; Walker RC; Ansell SM; Macon WR; Gores GG; Stegall MD; McGregor CG
J Clin Oncol; 2005 Oct; 23(30):7574-82. PubMed ID: 16186599
[TBL] [Abstract][Full Text] [Related]
12. [Successful treatment with L-asparaginase-based combination chemotherapy for refractory T-cell post-transplant lymphoproliferative disorder].
Mihara A; Chen CK; Yokoyama K; Ueda T; Tsukada Y; Awaya N; Mori T; Ikeda Y; Okamoto S
Rinsho Ketsueki; 2007 Apr; 48(4):305-9. PubMed ID: 17515121
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study.
Maksten EF; Vase MØ; Kampmann J; d'Amore F; Møller MB; Strandhave C; Bendix K; Bistrup C; Thiesson HC; Søndergaard E; Hamilton-Dutoit S; Jespersen B
Transpl Int; 2016 Apr; 29(4):483-93. PubMed ID: 26749337
[TBL] [Abstract][Full Text] [Related]
14. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
Sarkozy C; Kaltenbach S; Faurie P; Canioni D; Berger F; Traverse-Glehen A; Ghesquieres H; Salles G; Bachy E; Alyanakian MA; Hermine O; Neven B; Macintyre E; Romana S; Molina TJ; Suarez F; Asnafi V; Bruneau J
Genes Chromosomes Cancer; 2017 Mar; 56(3):221-230. PubMed ID: 27750397
[TBL] [Abstract][Full Text] [Related]
15. Expression of intratumoral forkhead box protein 3 in posttransplant lymphoproliferative disorders: clinical features and survival outcomes.
Berglund D; Kinch A; Edman E; Backlin C; Enblad G; Larsson E; Molin D; Pauksens K; Sundström C; Baecklund E
Transplantation; 2015 May; 99(5):1036-42. PubMed ID: 25211518
[TBL] [Abstract][Full Text] [Related]
16. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
17. Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.
Rosenberg AS; Klein AK; Ruthazer R; Evens AM
Am J Hematol; 2016 Jun; 91(6):560-5. PubMed ID: 26928381
[TBL] [Abstract][Full Text] [Related]
18. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
Wasson S; Zafar MN; Best J; Reddy HK
J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
[TBL] [Abstract][Full Text] [Related]
20. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
